Related Experiment Video
Updated: Dec 14, 2025
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Treatment of ErbB2 breast cancer by mitochondrial targeting
Sophia Eldad1, Rachel Hertz1, Gilad Vainer2
1Dept of Human Nutrition and Metabolism, Hebrew University Medical School, 91120 Jerusalem, Israel.
Background:
ErbB2 breast cancer still remains an unmet need due to primary and/or acquired resistance to current treatment strategies. MEDICA compounds consist of synthetic long-chain α,ω-dicarboxylic acids previously reported to suppress breast cancer in PyMT transgenic mice.
Methods:
MEDICA efficacy and mode of action in the ErbB2 context was studied in ErbB2 transgenic mice and human breast cancer cells.
Results:
MEDICA treatment is shown here to suppress ErbB2 breast tumors and lung metastasis in ErbB2/neu MMTV transgenic mice, to suppress ErbB2/neu xenografts in nod/scid mice, and to suppress survival of AU565 and BT474 human ErbB2 breast cancer cells. Suppression of ErbB2 breast tumors by MEDICA is due to lipid raft disruption with loss of ErbB family members, including EGFR, ErbB2, and ErbB3. In addition, MEDICA inhibits mTORC1 activity, independently of abrogating the ErbB receptors and their signaling cascades. The double hit of MEDICA in abrogating ErbB and mTORC1 is partly accounted for by targeting mitochondria complex I.
Conclusions:
Mitochondrial targeting by MEDICA suppresses ErbB2 breast tumors and metastasis due to lipid raft disruption and inhibition of mTORC1 activity. Inhibition of mTORC1 activity by MEDICA avoids the resistance acquired by canonical mTORC1 inhibitors like rapalogs or mTOR kinase inhibitors.
Insights
MEDICA compounds suppress ErbB2 breast cancer by disrupting lipid rafts and inhibiting mTORC1 signaling, offering a novel therapeutic strategy. This dual action targets mitochondria, potentially overcoming resistance to existing treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- ErbB2-positive breast cancer presents resistance challenges to current therapies.
- MEDICA compounds, synthetic long-chain α,ω-dicarboxylic acids, show prior efficacy in preclinical breast cancer models.
Purpose of the Study:
- To investigate the efficacy and mechanism of action of MEDICA compounds in ErbB2-positive breast cancer.
- To evaluate MEDICA's potential in overcoming treatment resistance.
Main Methods:
- Studies were conducted in ErbB2 transgenic mice, xenograft models (nod/scid mice), and human ErbB2 breast cancer cell lines (AU565, BT474).
- Mechanistic studies involved assessing lipid raft integrity, ErbB receptor expression, mTORC1 activity, and mitochondrial complex I function.
Main Results:
- MEDICA treatment suppressed primary ErbB2 breast tumors and lung metastasis in vivo.
- MEDICA disrupted lipid rafts, leading to the loss of ErbB family members (EGFR, ErbB2, ErbB3) and inhibited mTORC1 signaling.
- The compound's effects were partly attributed to targeting mitochondrial complex I, demonstrating a dual inhibitory mechanism.
Conclusions:
- MEDICA effectively suppresses ErbB2 breast tumors and metastasis through lipid raft disruption and mTORC1 inhibition.
- This dual mechanism, including mitochondrial targeting, offers a promising approach to circumvent resistance associated with conventional mTORC1 inhibitors.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...